(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 29 September 2005 (29.09.2005)

PCT

(10) International Publication Number WO 2005/090284 A1

(51) International Patent Classification7: C07C 233/00, 237/00

(21) International Application Number:

PCT/EP2005/002920

- (22) International Filing Date: 18 March 2005 (18.03.2005)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 04006461.0

18 March 2004 (18.03.2004)


- (71) Applicant (for all designated States except US): REVOTAR BIOPHARMACEUTICALS AG [DE/DE]; Neuendorfstrasse 24a, 16761 Hennigsdorf (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): KRANICH, Remo [DE/DE]; Hennigsdorfer Str. 27d, 13503 Berlin (DE).


AYDT, Ewald, Mirko [DE/DE]; Lloyd-G.-Wells-Strasse 20, 14163 Berlin (DE).

- (74) Agent: ISENBRUCK, Günter; Isenbruck Bösl Hörschler Wichmann Huhn, Theodor-Heuss-Anlage 12, 68165 Mannheim (DE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN. CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM. ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: NON-GLYCOSYLATED/NON-GLYCOSIDIC/NON-PEPTIDIC SMALL MOLECULE PSGL-1 MIMETICS FOR THE TREATMENT OF INFLAMMATORY DISORDERS





(57) Abstract: Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier which is useful in a medicine, formula (Ia) and formula (Ib), wherein the symbols, indices and substituents have the following meaning R1=H, CN, NO2, CF3, F, Cl, Br, I, CH₃ R²=H, CN, NO₂, CF₃, F, Cl, Br, I, CH₃, Et, n-Pr, i-Pr, n-Bu, t-Bu, phenyl, thienyl, furyl, thiazolyl and either R¹ or R² must be H R³=H, CN, NO₂, CF₃, F, Cl, Br, I, CH₃, Et, n-Pr, i-Pr, n-Bu, t-Bu, phenyl, thienyl, furyl, thiazolyl then X is e.g., formula (II), or, formula (III), with R4 being H, CH₃, CH₂CH₃ or, formula (IV), or, formula (V), and Y being, formula (VI), or, formula (VII), or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds of formula (Ia) or (Ib). The compounds are applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

WO 2005/090284 A1



GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG):

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.